Update on chemotherapeutic approaches and management of bevacizumab usage for glioblastoma

Yusuke Funakoshi, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, yuhei sangatsuda, Yutaka Fujioka, Kosuke Takigawa, Masahiro Mizoguchi

Research output: Contribution to journalReview articlepeer-review

Abstract

Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials, AVAglio and RTOG 0825, were performed. Bevacizumab was found to improve progression-free survival (PFS) and was reported to be beneficial for maintaining patient performance status as an initial treatment. These outcomes led to bevacizumab approval in Japan in 2013 as an insurance-covered first-line drug for glioblastoma concurrently with its second-line application. However, prolongation of overall survival was not evinced in these clinical trials; hence, the clinical benefit of bevacizumab for newly diagnosed glioblastomas remains controversial. A recent meta-analysis of randomized controlled trials of bevacizumab combined with temozolomide in recurrent glioblastoma also showed an effect only on PFS, and the benefit of bevacizumab even for recurrent glioblastoma is controversial. Here, we discuss the clinical impact of bevacizumab for glioblastoma treatment by reviewing previous clinical trials and real-world evidence by focusing on Japanese experiences. Moreover, the efficacy and safety of bevacizumab are summarized, and we provide suggestions for updating the approaches and management of bevacizumab.

Original languageEnglish
Article number470
Pages (from-to)1-21
Number of pages21
JournalPharmaceuticals
Volume13
Issue number12
DOIs
Publication statusPublished - Dec 2020

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Update on chemotherapeutic approaches and management of bevacizumab usage for glioblastoma'. Together they form a unique fingerprint.

Cite this